Head-to-head · free

Lycia Therapeutics Inc. vs Mirum Pharmaceuticals, Inc.

LYCA vs MIRM — return on capital, cash generation, margins and balance sheet side by side.

LYCA

0 / 0

measures where LYCA leads

MIRM

0 / 0

measures where MIRM leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureLYCAMIRM · FY2025
Revenue—$521.3M
Net income—(23.4M)
Revenue growth (yearly, multi-year)—128.5%
Free cash flow—$54.9M
Free cash flow margin—10.5%
Net cash / (debt)——
ROIC——
Return on equity—-8.6%
Gross margin—80.8%
Operating margin—-4.2%
Net debt / EBITDA—6.22x

Figures are as reported by each company; latest fiscal year shown.

Where Lycia Therapeutics Inc.'s cash went

Not reported yet.

Full LYCA profile →

Where Mirum Pharmaceuticals, Inc.'s cash went (FY2025)

Capital spending
$954000
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full MIRM profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons